Values as of: 2024-11-03
COMMON STOCK | Medical Devices |
Last Closing
USD 59.29Change
0.00 (0.00)%Market Cap
USD 8.98BVolume
2.08MAnalyst Target
USD 47.92Verdict
Verdict
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Company Website : https://www.bruker.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| DXCM | DexCom Inc |
N/A |
USD 27.48B |
| PODD | Insulet Corporation |
N/A |
USD 16.52B |
| MASI | Masimo Corporation |
N/A |
USD 7.71B |
| PRCT | Procept Biorobotics Corp |
N/A |
USD 4.99B |
| TMDX | TransMedics Group Inc |
N/A |
USD 4.17B |
| AXNX | Axonics Modulation Technologie.. |
N/A |
USD 3.60B |
| NARI | Inari Medical Inc |
N/A |
USD 2.85B |
| LIVN | LivaNova PLC |
N/A |
USD 2.80B |
| QDEL | Quidel Corporation |
N/A |
USD 2.62B |
| IRTC | iRhythm Technologies Inc |
N/A |
USD 2.37B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| TYNE | 12.61 % | 0.00 % |
N/A |
N/A | |
| JSMD | Janus Henderson Small/Mid.. | 1.80 % | 0.50 % |
N/A |
USD 0.38B |
| QRH:CA | 0.00 % | 1.20 % |
N/A |
N/A | |
| HLTH:AU | VanEck Global Healthcare .. | 0.00 % | 0.00 % |
N/A |
USD 0.06B |
| Market Performance vs. Industry/Classification (Medical Devices) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -19.31% | 39% | F | 29% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -19.31% | 39% | F | 30% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 0.80% | 40% | F | 36% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 0.80% | 40% | F | 38% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | 24.58% | 69% | C- | 62% | D | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 24.58% | 69% | C- | 62% | D | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 17.87% | 59% | D- | 72% | C | ||
| Dividend Return | 18.16% | 59% | D- | 71% | C- | ||
| Total Return | 0.29% | 50% | F | 10% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 36.53% | 75% | C | 52% | F | ||
| Risk Adjusted Return | 49.72% | 93% | A | 78% | C+ | ||
| Market Capitalization | 8.98B | 98% | N/A | 92% | A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company has under performed its peers on annual average total returns in the past 5 years.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median revenue growth in the previous 5 years compared to its sector
